Drug Details

General Information of the Drug (ID: DR7409)
Name
Rituximab
Molecular Type
Antibody
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Approved [1]
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 157-183 mg/L
Clearance
The clearance of drug is 0.335 L/day in rheumatoid arthritis patients
Half-life
The concentration or amount of drug in body reduced by one-half in 22 days
Metabolism
The drug is metabolized via opsonization via the reticuloendothelial system
Vd
The volume of distribution (Vd) of drug is 3.1 L
    Click to Show/Hide
TTD Drug ID
D09EXD
DrugBank ID
DB00073
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vincristine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Increase Tumor cell death
                    In-vitro Model Ramos CVCL_0597 Burkitt lymphoma Homo sapiens
                    Experimental
                    Result(s)		 Rituximab synergizes with vincristine in the killing of Ramos Burkitt's lymphoma B cell line.
          Pentostatin + Cladribine     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL.
Target and Pathway
Target(s) Leukocyte surface antigen Leu-16 (CD20)  Molecule Info  [4]
KEGG Pathway Hematopoietic cell lineage Click to Show/Hide
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
Reference 2 Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt's lymphoma B cell line. Cancer Biother Radiopharm. 2014 Mar;29(2):87-90.
Reference 3 Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011 Jun;52 Suppl 2:75-8.
Reference 4 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link